Clinical trial
Study of NS-9 in Patients With Liver Metastases
NCT00094003 · NS Pharma, Inc., Industry · Completed
Key facts
| NCT number | NCT00094003 |
|---|---|
| Title | Study of NS-9 in Patients With Liver Metastases |
| Official title | A Phase I, Open-Label, Dose Escalation Study of Intravenously Administered NS-9 in Subjects With Liver Metastases From Various Primary Cancers |
| Lead sponsor | NS Pharma, Inc., Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Liver Neoplasms, Neoplasm Metastasis, Local Neoplasm Recurrences |
| Intervention type | Drug |
| Interventions | NS-9 [Poly I: Poly C] |
| Enrollment | 20 |
| Start date | Sep 1, 2002 |
| First posted | Oct 11, 2004 |
| Last update posted | Nov 11, 2005 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: